Recent Updates
Recently added Catalysts

Reviva Pharmaceuticals Holdings, Inc.

RVPH
UndervaluedPharma · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$0.43
▲ +0.03 · +8.67%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full RVPH financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.2652W HIGH $23.20
Volume
74.03 K
Value Traded
31.58 K
Short % Float
0.41%
-58.48%Week
-55.77%1 Month
-93.33%3 Month
-96.61%6 Month
-99.62%5 Year
-99.82%All Time

Cash Data

Unlock RVPH cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
4.51 M
EPS (TTM)
-6.75
P/E Ratio
-
Ent. Value
-9.52 M
Total Shares
115.03 M
Float Shares
98.81 M
Insiders
1.95%
Institutions
17.92%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every RVPH catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

RVPH Catalyst Timeline

Dated clinical, regulatory and corporate events for Reviva Pharmaceuticals Holdings, Inc.

Unlock the full RVPH catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How RVPH actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-11-03Brilaroxazine (RP5063) Phase 3 data readout Phase 3
Unlock 1 more RVPH historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D29 / 100
Pipeline Score
$17M
Pipeline Value
Undervalued
Valuation Signal
2
Drugs Scored
3.7x
rNPV / MCap
Reviva Pharmaceuticals Holdings, Inc. faces pipeline headwinds (29/100), with $132M risk-adjusted pipeline value, led by RP5063 in Acute Schizophrenia (Phase 2).
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
RP5063 Small moleculeCompletedNCT01490086Acute SchizophreniaPhase 2 COMPLETED 234Mar 1, 2013
Unlock the RVPH pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every RVPH program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
brilaroxazine schizophreniaPhase 32026-04-2350 mg of brilaroxazine vs. placebo, with a generally well-tolerated side effect profile comparable to placebo and discontinuation rates lower than placeboRead MoreReviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric IndicationsRead More
Scroll for more · summaries link to the source press release
Unlock every RVPH trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock RVPH insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Prabhu NarayanOfficer (Chief Financial Officer)Grant/Award 40,925 40,925 held$0.00 03/18/2026
Unlock the full RVPH insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in RVPH

Fund % of Portfolio Current MV Shares Owned Activity
Avidity Partners 0 % 52.00 K 138.00 K
Unlock every fund holding RVPH
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in RVPH
Shares held by hedge funds each quarter, and who bought or sold.

RVPH Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-10-16
Unlock RVPH option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live RVPH option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock RVPH options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How RVPH ranks across every disease it competes in

Competitive Position is a premium feature
See how RVPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

RVPH News

About Reviva Pharmaceuticals Holdings, Inc.

14 employees
BIOPHARMAWATCH ELITE PLUS
Trade the next RVPH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime